{"id":522027,"date":"2021-08-03T08:03:21","date_gmt":"2021-08-03T12:03:21","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-update-at-the-upcoming-btig-virtual-biotechnology-conference\/"},"modified":"2021-08-03T08:03:21","modified_gmt":"2021-08-03T12:03:21","slug":"cue-biopharma-to-present-corporate-update-at-the-upcoming-btig-virtual-biotechnology-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-update-at-the-upcoming-btig-virtual-biotechnology-conference\/","title":{"rendered":"Cue Biopharma to Present Corporate Update at the\u00a0Upcoming BTIG Virtual Biotechnology Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE, Mass., Aug.  03, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BTGemvheby0zcy8tsrSAhQeBePDJYsjVQ6W-GKb-ENye5s69GdWAOYLgoWgfuzlagJQmyZbu1oCSWJRVUniOpYePwZIG2P7O04lAdMZrrs4=\" rel=\"nofollow noopener\" target=\"_blank\">Cue Biopharma, Inc.<\/a> (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient\u2019s body, announced today that it will participate in a fireside chat at the BTIG Virtual Biotechnology Conference being held August 9-10 2021.<\/p>\n<p>During the fireside chat, Cue Biopharma will provide a corporate update highlighting clinical progress on CUE-101, the lead Immuno-STAT\u2122 <em>(Selective Targeting and Alteration of T cells)<\/em> IL-2 based therapeutic, in clinical trials for the treatment of second line and beyond patients with HPV+ recurrent\/metastatic head and neck cancer. The presentation will also focus on the Company\u2019s platform developments and pipeline progress including its next clinical candidate CUE-102, targeting the Wilms\u2019 tumor 1 (WT1) antigen, which will be evaluated in a Phase 1 clinical trial expected to commence in 1H22.<\/p>\n<p><strong>Presentation Details<\/strong><\/p>\n<p><strong>BTIG Virtual Biotechnology Conference<\/strong><br \/><strong>Date and Time:<\/strong> Tuesday, August 10, 2021 at 3:00 p.m. EDT<\/p>\n<p><em>The webcasted fireside chat will be hosted on the conference website and available only to conference participants. Please visit <\/em><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PJnth95eE2t_uw8Fpetd12FDbn59UdD9eVvGxgAvbIXZMz69IMzEMXy37xljV3Z7m7_E2aR8loMSS5x-xozmOcxk8QnQOTp97aQ0hVt1aRs=\" rel=\"nofollow noopener\" target=\"_blank\"><em>www.BTIG.com<\/em><\/a><em> for more information.<\/em><\/p>\n<p>\n        <strong>About\u00a0BTIG <\/strong><br \/>\n        <br \/>BTIG is a global financial services firm specializing in institutional trading, investment banking, research and related brokerage services. With an extensive global footprint and more than 650 employees, BTIG, LLC and its affiliates operate out of 19 cities throughout the U.S., and in Europe, Asia and Australia. BTIG offers execution, expertise and insights for equities, equity derivatives, ETFs and fixed income, currency and commodities (futures, interest rates, credit, and convertible and preferred securities). The firm\u2019s core capabilities include global execution, portfolio, electronic and outsource trading, transition management, investment banking, prime brokerage, capital introduction, corporate access, research and strategy, commission management and more.<\/p>\n<p>\n        <strong>About\u00a0Cue Biopharma<\/strong><br \/>\n        <br \/>Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient\u2019s body to transform the treatment of cancer, infectious disease and autoimmune disease. The company\u2019s proprietary Immuno-STAT\u2122 <em>(Selective Targeting and Alteration of T cells)<\/em> platform, is designed to harness the body\u2019s intrinsic immune system without the need for ex vivo manipulation.<\/p>\n<p>Headquartered in Cambridge, Massachusetts, the company is led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.<\/p>\n<p>For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SL_4bF9_azdEBw_AjO7rOLLHtevZJh3P7rns97JV5NSwOyj-UCXfWryac28UfDD_q0eWrPrebvoxt9Hf0sj9Z-cgYxqHSXGiBqjh6uJexKM=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.cuebiopharma.com<\/a> and follow us on Twitter at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SL_4bF9_azdEBw_AjO7rOKPze5ZZNp0wf-lo0_pR6FqLaneC7tFxNJqr5krlIsvDaIV4h3gUhMEWPx3BpDDp0qcllejIscQcHWSeTmbaOaEPtdE__iOh0O1YUVccr2AP\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/twitter.com\/CueBiopharma<\/a>.<\/p>\n<p>\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>George B. Zavoico, Ph.D.<br \/>VP, Investor Relations &amp; Corporate Development <br \/>Cue Biopharma, Inc. <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SnaqjvMeKD2FJ8oo83s2dLNsG21r2xB11C2lJFRKvBjDAG-N5U9Zc0QJLvbIieDQYzW0ywtYwHYqu-g5W-JnIWkB0Tt6Wc1imPkRv3aUcoI=\" rel=\"nofollow noopener\" target=\"_blank\">gzavoico@cuebio.com<\/a><\/p>\n<p>\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Darren Opland, Ph.D.<br \/>LifeSci Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=20iHj-dSaZGoV82d9MtUssbezLhY5I-xMc8G2XzM0kq_-jVHDZIXUAB0pkmIuDNPn9BDESAuTyYuSqeNkkPdiDCiQq5ZHTbLDx-x_OPUXH8=\" rel=\"nofollow noopener\" target=\"_blank\">darren@lifescicomms.com<\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NzA0NiM0MzE1Njc5IzIwOTI2OTI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/8a25b6f4-618e-4114-9741-5f6174fa3b20\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) &#8212; Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient\u2019s body, announced today that it will participate in a fireside chat at the BTIG Virtual Biotechnology Conference being held August 9-10 2021. During the fireside chat, Cue Biopharma will provide a corporate update highlighting clinical progress on CUE-101, the lead Immuno-STAT\u2122 (Selective Targeting and Alteration of T cells) IL-2 based therapeutic, in clinical trials for the treatment of second line and beyond patients with HPV+ recurrent\/metastatic head and neck cancer. The presentation will also focus on the Company\u2019s platform developments and pipeline progress &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-update-at-the-upcoming-btig-virtual-biotechnology-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cue Biopharma to Present Corporate Update at the\u00a0Upcoming BTIG Virtual Biotechnology Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-522027","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cue Biopharma to Present Corporate Update at the\u00a0Upcoming BTIG Virtual Biotechnology Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-update-at-the-upcoming-btig-virtual-biotechnology-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cue Biopharma to Present Corporate Update at the\u00a0Upcoming BTIG Virtual Biotechnology Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) &#8212; Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient\u2019s body, announced today that it will participate in a fireside chat at the BTIG Virtual Biotechnology Conference being held August 9-10 2021. During the fireside chat, Cue Biopharma will provide a corporate update highlighting clinical progress on CUE-101, the lead Immuno-STAT\u2122 (Selective Targeting and Alteration of T cells) IL-2 based therapeutic, in clinical trials for the treatment of second line and beyond patients with HPV+ recurrent\/metastatic head and neck cancer. The presentation will also focus on the Company\u2019s platform developments and pipeline progress &hellip; Continue reading &quot;Cue Biopharma to Present Corporate Update at the\u00a0Upcoming BTIG Virtual Biotechnology Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-update-at-the-upcoming-btig-virtual-biotechnology-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-03T12:03:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NzA0NiM0MzE1Njc5IzIwOTI2OTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-corporate-update-at-the-upcoming-btig-virtual-biotechnology-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-corporate-update-at-the-upcoming-btig-virtual-biotechnology-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cue Biopharma to Present Corporate Update at the\u00a0Upcoming BTIG Virtual Biotechnology Conference\",\"datePublished\":\"2021-08-03T12:03:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-corporate-update-at-the-upcoming-btig-virtual-biotechnology-conference\\\/\"},\"wordCount\":459,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-corporate-update-at-the-upcoming-btig-virtual-biotechnology-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NzA0NiM0MzE1Njc5IzIwOTI2OTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-corporate-update-at-the-upcoming-btig-virtual-biotechnology-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-corporate-update-at-the-upcoming-btig-virtual-biotechnology-conference\\\/\",\"name\":\"Cue Biopharma to Present Corporate Update at the\u00a0Upcoming BTIG Virtual Biotechnology Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-corporate-update-at-the-upcoming-btig-virtual-biotechnology-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-corporate-update-at-the-upcoming-btig-virtual-biotechnology-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NzA0NiM0MzE1Njc5IzIwOTI2OTI=\",\"datePublished\":\"2021-08-03T12:03:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-corporate-update-at-the-upcoming-btig-virtual-biotechnology-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-corporate-update-at-the-upcoming-btig-virtual-biotechnology-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-corporate-update-at-the-upcoming-btig-virtual-biotechnology-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NzA0NiM0MzE1Njc5IzIwOTI2OTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NzA0NiM0MzE1Njc5IzIwOTI2OTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-corporate-update-at-the-upcoming-btig-virtual-biotechnology-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cue Biopharma to Present Corporate Update at the\u00a0Upcoming BTIG Virtual Biotechnology Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cue Biopharma to Present Corporate Update at the\u00a0Upcoming BTIG Virtual Biotechnology Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-update-at-the-upcoming-btig-virtual-biotechnology-conference\/","og_locale":"en_US","og_type":"article","og_title":"Cue Biopharma to Present Corporate Update at the\u00a0Upcoming BTIG Virtual Biotechnology Conference - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) &#8212; Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient\u2019s body, announced today that it will participate in a fireside chat at the BTIG Virtual Biotechnology Conference being held August 9-10 2021. During the fireside chat, Cue Biopharma will provide a corporate update highlighting clinical progress on CUE-101, the lead Immuno-STAT\u2122 (Selective Targeting and Alteration of T cells) IL-2 based therapeutic, in clinical trials for the treatment of second line and beyond patients with HPV+ recurrent\/metastatic head and neck cancer. The presentation will also focus on the Company\u2019s platform developments and pipeline progress &hellip; Continue reading \"Cue Biopharma to Present Corporate Update at the\u00a0Upcoming BTIG Virtual Biotechnology Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-update-at-the-upcoming-btig-virtual-biotechnology-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-03T12:03:21+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NzA0NiM0MzE1Njc5IzIwOTI2OTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-update-at-the-upcoming-btig-virtual-biotechnology-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-update-at-the-upcoming-btig-virtual-biotechnology-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cue Biopharma to Present Corporate Update at the\u00a0Upcoming BTIG Virtual Biotechnology Conference","datePublished":"2021-08-03T12:03:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-update-at-the-upcoming-btig-virtual-biotechnology-conference\/"},"wordCount":459,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-update-at-the-upcoming-btig-virtual-biotechnology-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NzA0NiM0MzE1Njc5IzIwOTI2OTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-update-at-the-upcoming-btig-virtual-biotechnology-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-update-at-the-upcoming-btig-virtual-biotechnology-conference\/","name":"Cue Biopharma to Present Corporate Update at the\u00a0Upcoming BTIG Virtual Biotechnology Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-update-at-the-upcoming-btig-virtual-biotechnology-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-update-at-the-upcoming-btig-virtual-biotechnology-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NzA0NiM0MzE1Njc5IzIwOTI2OTI=","datePublished":"2021-08-03T12:03:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-update-at-the-upcoming-btig-virtual-biotechnology-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-update-at-the-upcoming-btig-virtual-biotechnology-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-update-at-the-upcoming-btig-virtual-biotechnology-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NzA0NiM0MzE1Njc5IzIwOTI2OTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NzA0NiM0MzE1Njc5IzIwOTI2OTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-update-at-the-upcoming-btig-virtual-biotechnology-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cue Biopharma to Present Corporate Update at the\u00a0Upcoming BTIG Virtual Biotechnology Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/522027","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=522027"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/522027\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=522027"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=522027"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=522027"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}